Lynn Bekris, PhD

Assistant Staff

  • Genomic Medicine Institute
  • Lerner Research Institute
  • 9500 Euclid Avenue
  • Cleveland, Ohio 44195
  • Phone: (216) 444-0111
  • Fax: (216) 636-0009

Biomarkers and Alzheimer's disease Research 

Areas of interest are:

1)    Genes within biological pathways relevant to AD pathogenesis and their association with known cerebrospinal fluid biomarkers, such as Abeta and Tau. So far we have identified multiple genetic variants associated with cerebrospinal fluid apoE, APP, Abeta or tau levels. Next, using statistical methods and bioinformatics we will investigate possible combinatorial associations between these variants in AD.

2)    Assocations between non-coding RNA levels and AD. So far, in a small pilot study, we identified one plasma microRNA that was uniquely present in patients with Alzheimer’s disease. Next, we will measure microRNA levels in another larger cohort and study the functional impact of AD specific microRNA on gene regulation.

3)    Disruption of normal function by genetic variants. In this work our lab produces libraries of genetic variants. These libraries are used to study how these variants might disrupt normal function or how certain small molecules might correct this disruption of function.

There is no treatment that stops cognitive decline in Alzheimer’s disease or other dementias.  Biomarker research is critical for the development of treatments that will prevent or cure Alzheimer’s disease. 

In other words ...

Our research is focused on identifying and evaluating the functional impact of genetic and epigenetic markers of Alzheimer’s disease.

  • Rumana Akhter, PhD
  • Postdoctoral Fellow
  • Location:NE5-216
  • Phone:(216) 444-4816
  • Giana D'Aleo, MS
  • Bioinformatics Technologist
  • Location:NE5-216
  • Phone:(216) 444-1142
  • Shane Formica, MS
  • Senior Research Technologist
  • Location:NE5-216
  • Phone:(216) 444-1142
  • Maria Khrestian, MS
  • Research Technologist
  • Location:NE5-216
  • Phone:(216) 444-4816
  • Yvonne Shao PhD
  • Lead Research Technologist
  • Location:NE5-216
  • Phone:(216) 444-4816
  • Fax:(216) 636-0009

  1. Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM. Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiol Aging. 2013 Sep 4.
  2. Yu CE, Cudaback E, Foraker J, Thomson Z, Leong L, Lutz F, Gill JA, Saxton A, Kraemer B, Navas P, Keene CD, Montine T, Bekris LM. Epigenetic signature and enhancer activity of the human APOE gene. Hum Mol Genet. 2013 Aug 7.
  3. Bekris LM, Lutz F, Montine TJ, Yu CE, Tsuang D, Peskind ER, Leverenz JB. MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers. 2013 Aug;18(5):455-66.
  4. Bekris L.M.,Millard S.,Lutz F.  Li G.,   Galasko D.R.,  Farlow M.R., Quinn J.F., Kaye J.A., Leverenz J.B., Tsuang D.W.,  Montine T.J., Yu C.E. Peskind E.R.  Tau Phosphorylation Pathway Genes and Cerebrospinal Fluid Tau Levels in Alzheimer’s Disease. Am J Med Genet B Neuropsychiatr Genet. 2012 Oct;159B(7):874-83
  5. Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Montine TJ, Peskind ER, Yu CE. ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiol Aging. 2012 Sep;33(9):2229.e1-2229.e9.
  6. Bekris LM, Lutz F, Yu CE. Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. J Hum Genet. 2012 Jan;57(1):18-25.
  7. Bekris LM, Galloway NM, Millard S, Lockhart D, Wijsman E, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer’s disease. Neurobiol Aging. 2011 Mar;32(3):556.e13-23.
  8. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010 Dec;23(4):213-27. Review.
  9. Bekris LM, Mata IF, Zabetian CP. The Genetics of Parkinson Disease. J Geriatr Psychiatry Neurol. 2010 Dec;23(4):228-42. Review.
  10. Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):409-17.
  11. Bekris LM, Millard S, Galloway NM, Vuletic S, Albers JJ,  Li G,   Galasko DR,  DeCarli C, Farlow MR, Clark CM, Quinn JF,Kaye JA, Schellenberg GD,  Tsuang D, Peskind ER, Yu CE. Multiple SNPs within and surrounding the Apolipoprotein E Gene Influence Cerebrospinal Fluid Apolipoprotein E Protein Levels. J Alzheimers Dis. 2008 Apr;13(3):255-66.
  12. Bekris LM, Shephard C, Janer M, Graham J, McNeney B, Shin J, Zarghami M, Griffith W, Farin F, Kavanagh TJ, Lernmark A. Glutamate cysteine ligase catalytic subunit promoter polymorphisms and associations with type 1 diabetes age-at-onset and GAD65 autoantibody levels. Exp Clin Endocrinol Diabetes. 2007 Apr;115(4):221-8.
  13. Bekris LM, Jensen RA, Lagerquist E, Hall TR, Agardh CD, Cilio CM, Lethagen, AL, Lernmark A, Robertson JA, Hampe CS. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination.  Diabet Med. 2007 Mar 15. May;24(5):521-6.
  14. Bekris LM, Viernes HM, Farin FM, Maier LA, Kavanagh TJ, Takaro TK. Chronic beryllium disease and glutathione biosynthesis genes. J Occup Environ Med. 2006 Jun;48(6):599-606.
  15. Bekris LM, Kavanagh TJ, Lernmark A. Targeting type 1 diabetes before and at the clinical onset of disease. Endocr Metab Immune Disord Drug Targets. 2006 Mar;6(1):103-24. Review.
  16. Bekris LM, Shephard C, Peterson M, Hoehna J, Yserloo BV, Rutledge E, Farin F, Kavanagh TJ, Lernmark A. Glutathione-s-transferase M1 and T1 polymorphisms and associations with type 1 diabetes age-at-onset. Autoimmunity. 2005 Dec;38(8):567-75.
  17. Chessler SD, Hampe CS, Ortqvist E, Simonson WT, Bekris L. Immune reactivity to GAD25 in type 1 diabetes mellitus.  Autoimmunity. 2002 Aug;35(5):335-41.